| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Jean A Frazier, Louise Glassner Cohen, Leslie Jacobsen, Dale Grothe, James Flood, Ross J Baldessarini, Stephen Piscitelli, Grace S Kim, Judith L Rapopor. Clozapine pharmacokinetics in children and adolescents with childhood-onset schizophrenia. Journal of clinical psychopharmacology. vol 23. issue 1. 2003-05-07. PMID:12544379. |
clozapine pharmacokinetics in children and adolescents with childhood-onset schizophrenia. |
2003-05-07 |
2023-08-12 |
Not clear |
| Rajesh Narendran, Carolyn M Young, Cynthia A Pristach, Michele T Pato, Antoinette M Valenti, Alice R Fas. Efficacy of clozapine in the treatment of atypical antipsychotic refractory schizophrenia: a pilot study. Journal of clinical psychopharmacology. vol 23. issue 1. 2003-05-07. PMID:12544385. |
efficacy of clozapine in the treatment of atypical antipsychotic refractory schizophrenia: a pilot study. |
2003-05-07 |
2023-08-12 |
Not clear |
| Yuan-Hwa Chou, Christer Halldin, Lars Fard. Occupancy of 5-HT1A receptors by clozapine in the primate brain: a PET study. Psychopharmacology. vol 166. issue 3. 2003-05-07. PMID:12589516. |
the serotonin 5-hydroxytryptamine-1a (5-ht(1a)) receptor subtype has been suggested to play a role in the pathophysiology of schizophrenia and is one among several central neuroreceptors for which clozapine has moderate affinity in vitro. |
2003-05-07 |
2023-08-12 |
Not clear |
| Deanna L Kelly, Elizabeth A Gale, Robert R Conle. Clozapine treatment in patients with prior substance abuse. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 48. issue 2. 2003-05-01. PMID:12655909. |
this study examined outcomes following discharge on clozapine for treatment-resistant schizophrenia patients with and without diagnosed substance abuse histories. |
2003-05-01 |
2023-08-12 |
Not clear |
| C Barbui, A Danese, G Guaiana, L Mapelli, L Miele, E Monzani, M Percudan. Prescribing second-generation antipsychotics and the evolving standard of care in Italy. Pharmacopsychiatry. vol 35. issue 6. 2003-04-28. PMID:12518273. |
nearly 80 % of patients receiving clozapine had schizophrenia compared to less than 50 % of those receiving other second-generation antipsychotics. |
2003-04-28 |
2023-08-12 |
Not clear |
| Antona Wagstaff, Caroline Perr. Clozapine: in prevention of suicide in patients with schizophrenia or schizoaffective disorder. CNS drugs. vol 17. issue 4. 2003-04-28. PMID:12665398. |
clozapine: in prevention of suicide in patients with schizophrenia or schizoaffective disorder. |
2003-04-28 |
2023-08-12 |
Not clear |
| Antona Wagstaff, Caroline Perr. Clozapine: in prevention of suicide in patients with schizophrenia or schizoaffective disorder. CNS drugs. vol 17. issue 4. 2003-04-28. PMID:12665398. |
clozapine (mean 274.2 mg/day; n = 490) had a greater preventive effect on suicidality among patients with schizophrenia or schizoaffective disorder at high risk for suicide than olanzapine (mean 16.6 mg/day; n = 490) in a randomised, rater-blinded, multicentre study (p < 0.05; a 22-24% improvement). |
2003-04-28 |
2023-08-12 |
Not clear |
| Alan I Green, Ellen S Burgess, Ree Dawson, Suzannah V Zimmet, Rael D Strou. Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone. Schizophrenia research. vol 60. issue 1. 2003-04-24. PMID:12505141. |
alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone. |
2003-04-24 |
2023-08-12 |
Not clear |
| Alan I Green, Ellen S Burgess, Ree Dawson, Suzannah V Zimmet, Rael D Strou. Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone. Schizophrenia research. vol 60. issue 1. 2003-04-24. PMID:12505141. |
we describe a retrospective study of the effects of the novel antipsychotics risperidone (risp) and clozapine on alcohol and cannabis use in patients with schizophrenia or schizoaffective disorder and comorbid alcohol and/or cannabis use disorder. |
2003-04-24 |
2023-08-12 |
Not clear |
| Adekola O Alao, Kamna Malhotra, Mantosh J Dewa. Comparing the side effect profile of the atypical antipsychotics. West African journal of medicine. vol 21. issue 4. 2003-04-22. PMID:12665274. |
post clozapine, the food and drug administration (fda) has approved the use of four newer atypical antipsychotics; risperidone, olanzapine, quetiapine and ziprasidone for the treatment of schizophrenia. |
2003-04-22 |
2023-08-12 |
Not clear |
| Steffen H Kristensen, Niels K Pørkse. [Clozapine and diabetic ketoacidosis]. Ugeskrift for laeger. vol 165. issue 5. 2003-04-10. PMID:12599849. |
we report a case of diabetic ketoacidosis in a 54-year-old white female with type 2 diabetes and schizophrenia during clozapine treatment. |
2003-04-10 |
2023-08-12 |
Not clear |
| Scott P Baymiller, Patricia Ball, Robert P McMahon, Robert W Buchana. Serum glucose and lipid changes during the course of clozapine treatment: the effect of concurrent beta-adrenergic antagonist treatment. Schizophrenia research. vol 59. issue 1. 2003-04-09. PMID:12413642. |
fifty subjects met the dsm-iii-r criteria for schizophrenia or schizoaffective disorder, participated in a 10-week, double-blind comparison of haloperidol and clozapine and a 1-year, open-label clozapine trial, and had available serum glucose and lipid levels. |
2003-04-09 |
2023-08-12 |
human |
| Ana García-Osta, Diana Frechilla, Joaquín Del Rí. Reduced basal and phencyclidine-induced expression of heat shock protein-70 in rat prefrontal cortex by the atypical antipsychotic abaperidone. Progress in neuro-psychopharmacology & biological psychiatry. vol 27. issue 1. 2003-04-01. PMID:12551723. |
since hsp70 has been associated to some schizophrenia symptoms, we suggest that reduced hsp70 in the prefrontal cortex, a cortical area that plays a critical role in the etiology of many schizophrenia symptoms, may be linked to an atypical profile of antipsychotics, such as clozapine, and possibly also abaperidone. |
2003-04-01 |
2023-08-12 |
rat |
| Veena Kumari, Tonmoy Sharm. Effects of typical and atypical antipsychotics on prepulse inhibition in schizophrenia: a critical evaluation of current evidence and directions for future research. Psychopharmacology. vol 162. issue 2. 2003-03-26. PMID:12110987. |
currently, available data on the differential effects of typical and atypical antipsychotics suggest that atypical antipsychotics, in particular clozapine and risperidone, may be more effective than typical antipsychotics in improving ppi deficits in schizophrenia. |
2003-03-26 |
2023-08-12 |
Not clear |
| Michael Mueck-Weymann, Thomas Rechlin, Franz Ehrengut, Robert Rauh, Jens Acker, Ralf W Dittmann, Jörg Czekalla, Peter Joraschky, Dominique Musselma. Effects of olanzapine and clozapine upon pulse rate variability. Depression and anxiety. vol 16. issue 3. 2003-03-21. PMID:12415532. |
twenty patients with schizophrenia (according to dsm-iii-r criteria) treated with either clozapine (100-600 mg/day) or olanzapine (10-20 mg/day), and ten healthy controls, were recruited into the study. |
2003-03-21 |
2023-08-12 |
Not clear |
| A Sénéchal, P Landry, R Deschamps, M Lessar. [Neutropenia in a patient treated with clozapine in combination with other psychotropic drugs]. L'Encephale. vol 28. issue 6 Pt 1. 2003-03-21. PMID:12506270. |
clozapine is an atypical antipsychotic known for its efficacy in refractory schizophrenia. |
2003-03-21 |
2023-08-12 |
Not clear |
| Johanna K Simosky, Karen E Stevens, Lawrence E Adler, Robert Freedma. Clozapine improves deficient inhibitory auditory processing in DBA/2 mice, via a nicotinic cholinergic mechanism. Psychopharmacology. vol 165. issue 4. 2003-03-20. PMID:12459928. |
the atypical antipsychotic clozapine also normalizes this deficit in schizophrenia patients, but by an unknown mechanism. |
2003-03-20 |
2023-08-12 |
mouse |
| Jean-Pierre Lindenmayer, Pal Czobor, Jan Volavka, Leslie Citrome, Brian Sheitman, Joseph P McEvoy, Thomas B Cooper, Miranda Chakos, Jeffrey A Lieberma. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. The American journal of psychiatry. vol 160. issue 2. 2003-03-04. PMID:12562575. |
the authors' goal was to assess the effects of clozapine, olanzapine, risperidone, and haloperidol on glucose and cholesterol levels in hospitalized patients with schizophrenia or schizoaffective disorder during a randomized double-blind 14-week trial. |
2003-03-04 |
2023-08-12 |
Not clear |
| D Mancama, M J Arranz, J Munro, S Osborne, A Makoff, D Collier, R Kerwi. Investigation of promoter variants of the histamine 1 and 2 receptors in schizophrenia and clozapine response. Neuroscience letters. vol 333. issue 3. 2003-01-30. PMID:12429384. |
investigation of promoter variants of the histamine 1 and 2 receptors in schizophrenia and clozapine response. |
2003-01-30 |
2023-08-12 |
Not clear |
| Michele Fabrazzo, Silvestro La Pia, Palmiero Monteleone, Giuseppina Esposito, Antonio Pinto, Luigi De Simone, Rachele Bencivenga, Mario Ma. Is the time course of clozapine response correlated to the time course of clozapine plasma levels? A one-year prospective study in drug-resistant patients with schizophrenia. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 27. issue 6. 2003-01-24. PMID:12464462. |
in the present study, we assessed prospectively the clinical response to clozapine and the plasma levels of the drug and its major metabolites in 32 drug-resistant patients with schizophrenia kept on a fixed dose of 600 mg/day for 1 year four of the patients met response criteria at week 4 of treatment. |
2003-01-24 |
2023-08-12 |
Not clear |